Looking to invest?

Smart investment in academic brilliance

Investing Lifecycle

Parkwalk is the largest growth EIS fund manager, backing world-changing technologies from the UK’s leading universities and research institutions. We invest across the spinout lifecycle; as part of IP Group plc, we back companies from start-up to scale-up, with a proven record of delivering consistent investor returns.

Early Stage Funding

Parkwalk, IP Group's EIS business, provides capital for early-stage companies at the Pre-Seed, Seed, and Series A stages. Through dedicated EIS funds, we partner with universities to invest in spinout companies.

Core Capital

The central stage, led by IP Group, provides permanent balance sheet capital to help businesses bridge the gap between initial funding and significant growth.

Scale-Up Capital

For established companies, Private Funds managed by IP Group offer Science & tech scale-up capital. This final stage provides the investment needed for companies to expand and scale their operations.

Looking to invest?

If you’re interested in exploring investment opportunities with Parkwalk, please fill out the form or email us at sales@parkwalkadvisors.com.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Role (select one)
Select the funds you are interested in (select multiple)
Consent

Downloads

Where university innovation meets investor opportunity

Funds

We back companies with the potential to change how the world works, as well as the resilience to get there. Our portfolio spans the most transformative areas of deeptech innovation. This targeted approach lets us build a diversified portfolio of high-growth businesses, each grounded in breakthrough university research and designed to scale.

Explore our Funds

Flagship Funds

University Funds

Accelerators

Guide to EIS

For more information on EIS tax reliefs, visit our EIS Knowledge Hub. There, you will find a range of educational materials, including guides and articles designed to help you understand the benefits of the scheme.

Visit our EIS Knowledge Hub

Meet our companies

Portfolio

We back companies with the potential to change how the world works, as well as the resilience to get there. Our portfolio spans the most transformative areas of deeptech innovation. This targeted approach lets us build a diversified portfolio of high-growth businesses, each grounded in breakthrough university research and designed to scale.

Explore full portfolio
Software to streamline recruitment processes
MeVitae has developed software to streamline recruitment processes, using data-driven technology to attract, screen and retain top talent whilst building diverse and productive teams fairly. The software aims to eliminate 15 bias parameters using its suite of Artificial Intelligence-based solutions.
Institution
Oxford
  • AI Big Data & Software

Mevitae

MeVitae has developed software to streamline recruitment processes, using data-driven technology to attract, screen and retain top talent whilst building diverse and productive teams fairly. The software aims to eliminate 15 bias parameters using its suite of Artificial Intelligence-based solutions.
Sector
AI Big Data & Software
Institution
Oxford
Website
www.mevitae.com
A value-driven techbio company
Concr is a value-driven techbio company, spun out of the University of Cambridge, applying statistical learning and advanced modelling adopted from astrophysics to aid in the precision treatment of cancer patients. Concr’s online platform allows the storage, management and analysis of data generating actionable insights for cost-effective drug development and patient treatment.
Institution
Cambridge
  • Life Sciences

Concr

Concr is a value-driven techbio company, spun out of the University of Cambridge, applying statistical learning and advanced modelling adopted from astrophysics to aid in the precision treatment of cancer patients. Concr’s online platform allows the storage, management and analysis of data generating actionable insights for cost-effective drug development and patient treatment.
Sector
Life Sciences
Institution
Cambridge
Website
www.concr.co
Devices that transform neurological care
Mint Neurotechnologies Ltd (MintNeuro) is an innovative startup at the dynamic intersection of neurotechnology and semiconductors. MintNeuro is pioneering integrated circuit solutions for implantable medical devices targeting the management and treatment of neurological conditions. MintNeuro’s goal is to deliver scalable, less invasive, and highly efficient devices that transform neurological care.
Institution
Imperial College
  • Digital Health
  • MedTech

MintNeuro

Mint Neurotechnologies Ltd (MintNeuro) is an innovative startup at the dynamic intersection of neurotechnology and semiconductors. MintNeuro is pioneering integrated circuit solutions for implantable medical devices targeting the management and treatment of neurological conditions. MintNeuro’s goal is to deliver scalable, less invasive, and highly efficient devices that transform neurological care.
Sector
Digital Health, MedTech
Institution
Imperial College
Website
mintneuro.com

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.